Thursday 25 April 2019 ,
Thursday 25 April 2019 ,
Latest News
  • Stay alert against terror activities: PM
  • Sri Lanka blasts: Zayan’s body arrives in Dhaka
  • Unspeakable grief: 5 members of 1 family killed in Sri Lanka
  • Death for 2 Netrakona war criminals
  • Death toll rises to 359 in Sri Lanka bombings, more arrested
  • 2 ‘drug traders’ killed in Cox’s Bazar, Dhaka ‘gunfights’
  • Sri Lanka attacker studied in UK, says minister, amid warning more bombers on loose
16 April, 2019 00:00 00 AM

Recurrence score may cut costs for high-risk breast cancer care

drugs.com
Recurrence score may cut costs for high-risk breast cancer care

Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy, according to a study published in the March issue of the Journal of the National Comprehensive Cancer Network.

Michaela A. Dinan, Ph.D., from the Duke University School of Medicine in Durham, North Carolina, and colleagues used SEER-Medicare data to identify a nationally representative sample of 30,058 Medicare beneficiaries diagnosed with early-stage, estrogen receptor-positive breast cancer from 2005 through 2011. Associations between RS testing and overall and chemotherapy-specific costs were evaluated.

The researchers found that 17.5 percent of patients received RS testing; of these, 13.3 percent were initially clinically classified as low-risk, 69.5 percent as intermediate-risk, and 17.2 percent as high-risk. One year after diagnosis, mean costs were $35,940 overall, $51,127 for clinically high-risk disease, $33,225 for intermediate-risk disease, and $26,695 for low-risk disease. Similar trends were seen for chemotherapy-specific costs.

RS testing was associated with significantly lower costs among high-risk patients for both relative costs (cost ratio, 0.88) and absolute costs ($6,606). In low-risk and intermediate-risk patients, higher costs were mainly caused by higher noncancer costs. In analyses of all 64,996 patients aged ≥66 years, associations between RS testing and costs among high-risk patients were similar but less marked because of lower overall use of chemotherapy.

"In the big picture, the ability for RS testing to reduce either the cost of chemotherapy or total health costs may depend on the general distribution of patients who are clinically considered to be high-, intermediate-, or low-risk," Dinan said in a statement.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Parkinson’s disease is a slowly progressing, degenerative disorder of the nervous system; Parkinson’s disease has several distinguishing characteristics:…
Cancer professionals need to be aware quality of life is an abstract concept for many patients

Cancer professionals need to be aware quality of life is an abstract concept for many patients

It has been a long consult. Gently adjusting his father’s hearing aid, the attentive son asks: “Dad, you hear what the doctor is saying? The…
Parkinson's disease symptoms, causes, stages, treatment, and life expectancy

Parkinson's disease symptoms, causes, stages, treatment, and life expectancy

SIETSKE N. HEYN, PHD   CHARLES PATRICK DAVIS, MD, PHD   Parkinson's disease is the second most common neurodegenerative disorder and the…
10 Early warning signs of Parkinson's disease

10 Early warning signs of Parkinson's disease

How to tell if you or someone you love might have Parkinson's It can be hard to tell if you have Parkinson's disease. Here are the 10 signs you…
Parkinson’s: Can how you sleep determine if you’ll develop it?

Parkinson’s: Can how you sleep determine if you’ll develop it?

During a symposium held at NNI, Professor Eduardo Tolosa, a neurologist and world-renowned expert on Parkinson Disease (PD) from the University of Barcelona,…
Precise decoding of breast cancer cells creates new option for treatment

Precise decoding of breast cancer cells creates new option for treatment

Researchers at the University of Zurich and from IBM Research have investigated the varying composition of cancer and immune cells in over 100 breast…
Gastroenteritis (Stomach flu) in children: What should parents do

Gastroenteritis (Stomach flu) in children: What should parents do

Gastroenteritis (commonly known as stomach flu) causes discomfort due to the ensuing vomiting and diarrhoea, which are often accompanied by tummy pains…
Sleep myths 'damaging your health'

Sleep myths 'damaging your health'

JAMES GALLAGHER A team at New York University trawled the internet to find the most common claims about a good night's kip. Then, in a study published…
More TV, tablets: Attention issues at age 5

More TV, tablets: Attention issues at age 5

Five-year-olds who spend more than two hours a day in front of a smartphone or tablet may be at risk of attention problems, a new study suggests. Excessive…
15 Remedies for back pain relief

15 Remedies for back pain relief

CATHY WONG Back pain is a health concern for most people in the United States at some point in their lives and one of the most common reasons people miss…
Declaration on the occasion of world health day, april 7, 2019

Declaration on the occasion of world health day, april 7, 2019

On the occasion of World Health Day on 7 April 2019, PHM West Africa & Center (PHM WCA) denounces the rise of fundamentalism and violence in several…
Seminar on ‘Universal Health Coverage to Combat Non-Communicable Diseases’ held

Seminar on ‘Universal Health Coverage to Combat Non-Communicable Diseases’ held

North South University has organized a seminar on ‘Universal Health Coverage to Combat Non-Communicable Diseases’ to observe World Health…
Research, training stressed for flourishing homeopathy

Research, training stressed for flourishing homeopathy

Stressing on conducting research & training on homeopathy in the country, health experts at a seminar said that research can flourish  …
Statins failing to adequately reduce cholesterol in around half of patients

Statins failing to adequately reduce cholesterol in around half of patients

MARIE CLAIRE DORKING Statins are not effective for around half of people taking them, new research has revealed. The cholesterol-lowering drugs taken…
FDA approves Evenity (romosozumab-aqqg)

FDA approves Evenity (romosozumab-aqqg)

The U.S. Food and Drug Administration recently approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting